BioDelivery Sciences International, Inc. (NASDAQ:BDSI) CFO Paolantonio Ernest Robert De sold 64,155 shares of the business’s stock in a transaction on Friday, April 6th. The stock was sold at an average price of $2.09, for a total transaction of $134,083.95. Following the transaction, the chief financial officer now owns 97,731 shares of the company’s stock, valued at approximately $204,257.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
NASDAQ BDSI opened at $2.10 on Friday. The company has a debt-to-equity ratio of 5.37, a quick ratio of 1.29 and a current ratio of 1.52. BioDelivery Sciences International, Inc. has a 1 year low of $1.55 and a 1 year high of $3.60.
BioDelivery Sciences International (NASDAQ:BDSI) last released its quarterly earnings data on Thursday, March 15th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). BioDelivery Sciences International had a net margin of 8.52% and a return on equity of 22.93%. The company had revenue of $12.51 million during the quarter, compared to analyst estimates of $9.83 million. sell-side analysts predict that BioDelivery Sciences International, Inc. will post -0.74 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Broadfin Capital LLC boosted its stake in BioDelivery Sciences International by 5.1% in the fourth quarter. Broadfin Capital LLC now owns 4,634,119 shares of the specialty pharmaceutical company’s stock valued at $13,671,000 after acquiring an additional 223,253 shares in the last quarter. Royce & Associates LP boosted its stake in BioDelivery Sciences International by 43.0% in the fourth quarter. Royce & Associates LP now owns 1,848,600 shares of the specialty pharmaceutical company’s stock valued at $5,453,000 after acquiring an additional 555,800 shares in the last quarter. Northern Trust Corp boosted its stake in BioDelivery Sciences International by 0.9% in the second quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock valued at $394,000 after acquiring an additional 1,203 shares in the last quarter. Krilogy Financial LLC boosted its stake in BioDelivery Sciences International by 28.8% in the third quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock valued at $395,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in BioDelivery Sciences International in the fourth quarter valued at $310,000. Institutional investors own 45.82% of the company’s stock.
A number of equities analysts recently commented on the stock. HC Wainwright set a $4.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research note on Monday, March 19th. Cantor Fitzgerald reiterated a “buy” rating and set a $5.00 target price on shares of BioDelivery Sciences International in a research note on Thursday, March 15th. ValuEngine downgraded shares of BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Finally, Seaport Global Securities assumed coverage on shares of BioDelivery Sciences International in a research note on Friday, January 26th. They set a “buy” rating and a $5.00 target price for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $4.25.
COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/biodelivery-sciences-international-inc-bdsi-cfo-paolantonio-ernest-robert-de-sells-64155-shares.html.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.